Go to the page content
Obesity

A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight

Locations

Austria

Start date

25/09/2026

Identifiers

Trial ID NN9536-8797,
NCT number NCT07845578,
Eudract number Not Available

Summary

The purpose of the study is to determine the effect of semaglutide on gastric emptying in people with obesity. Participants will receive either semaglutide or placebo, and the treatment assigned will be decided by chance. Semaglutide is a medicine that doctors can already prescribe, while placebo contains no active medicine.

Trial Overview:

Condition

Obesity

Overweight

Treatment

DRUG: Semaglutide

DRUG: Placebo semaglutide

DRUG: Paracetamol

Study type

INTERVENTIONAL

Trial duration

Sep 25 2026 - Sep 11 2027

Participants

60

Phase

I

Are you eligible?

true

Gender

Male and female
true

Age

18 to 64 years old

Find out how you can participate

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.